File No. CT/166/23-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/23/000166

To,

M/s Novo Nordisk India Private Limited,
Nxt Tower-2, Floor 1&2,Embassy Manyata BusinessPark,
Nagavara Village, Kasaba Hobli, Bangalore-560045, India.

Sir,

With reference to your application No. GCT/CT04/FF/2023/41060 (GCT/166/23) dated 22-12-2023, please find enclosed herewith the permission in Form CT-06 for conduct of Phase 3 clinical trial titled, "**ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation", Protocol No.: NN6018-4914 Protocol Version 2.0, dated 12/October/2023 with a total of up-to 90 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

1) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

2) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

3) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

4) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

5) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

6) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

7) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

8) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

9) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

10) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

11) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

12) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

13) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

14) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

15) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

16) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

17) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

18) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

19) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=697F5E47D940985D8E03BDC902D0E1F1F3CFA2CC1E8B0A1A2A1F1E81, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.12.27 15:41:16 IST

(Dr Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

File No. CT/166/23-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s Novo Nordisk India Pvt. Ltd, NxtTower-2, Floor 1&2, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore- 560045 India Telephone No.:+91 8040303200FAX: +91 8041123518 E-Mail:NHMK@NOVONORDISK.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: NN6018-4914 Protocol Version 2.0, dated 12/October/2023** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c2769041015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=657F5E47D940985D8F03BDC902D0E1FE73CFA12A1A126EA94FA5701124A19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.01.24 17:28:30 IST

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Ziltivekimab C 30 mg/ml / placebo
Therapeutic class:	Anti inflammatory agent
Dosage form:	Solution for injection

Composition:

Table 1 Composition of ziltivekimab C drug product

Ingredient	Quantity per mL	Function	Reference to standard
Drug substance			
Ziltivekimab (DS Process C)	30 mg	Active pharmaceutical ingredient	Novo Nordisk A/S
Excipients			
Trehalose dihydrate	50 mg	Tonicity agent	Ph. Eur., USP, JP
L-Arginine monohydrochloride	14.75 mg	Viscosity lowering agent	Ph. Eur., USP, JP
L-Methionine	1.49 mg	Antioxidant	Ph. Eur., USP, JP
L-Histidine	3.10 mg	Buffer	Ph. Eur., USP, JP
Polysorbate 80	0.7 mg	Surfactant	Ph. Eur., USP, JP
Hydrochloric acid	q.s.[1]	pH adjustment	Ph. Eur., USP, JP
Sodium hydroxide	q.s.[1]	pH adjustment	Ph. Eur., USP, JP
Water for injection	Fill to 1 mL	Solvent	Ph. Eur., USP, JP

1: For adjustment to pH 6.0.

Indications: Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Kasturba Medical College and Hospital, Manipal Department of Cardiology, Madhavnagar, Manipal, Udupi, Karnataka, 576104	MAHE Ethics Committee, Manipal Academy of Higher Education.edu bldg Madhav Nagar, Manipal Udupi, Udupi, Karnataka -576104 ECR/191/Inst/KL/2013/RR-19	Dr. Tom Devasia
2.	All India Institute of Medical Sciences (AIIMS), Nagpur Plot No. 2, Sector - 20, MIHAN, Nagpur, Maharashtra, 441108	Institutional Ethics Committee for Clinical Trial All India Institute of Medical Sciences, Nagpur, M/S Director AIIMS, Plot No. 2, Sector - 20, 1st Floor, OPD Building, MIHAN, Nagpur, Maharashtra - 441108, India ECR/1392/Inst/MH/2020	Dr. Sagar Makode
3.	Malla Reddy Narayana Multispeciality Hospital 1-1-216, Suraram X Roads, Jeedimetla Venkatarama Colony, Suraram Hyderabad, Telangana, 500055	MRMCW -Institutional Ethics Committee Malla Reddy Medical College for Women, Suraram X Road, Quthbullapur Municipality, Jeedimetla Hyderabad, Telangana -500055, India	Dr. Ajmera Prakash

		ECR/981/Inst/AP/2017/RR-20	
4.	LPS Institute of Cardiology & Cardiac Surgery, GSVM Medical College Swaroop Nagar Kanpur, Uttar Pradesh, 208002	Ethics Committee GSVM Medical College Kanpur GSVM Medical College Kanpur, Swaroop Nagar, Kanpur, Uttar Pradesh-208002, India ECR/680/Inst/UP/2014/RR-20	Dr. Santosh Kumar Sinha
5.	Sanjay Gandhi Postgraduate Institute of Medical Sciences Raebareli Road Lucknow, Uttar Pradesh,226014	Institutional Ethics Committee Sanjay Gandhi Postgraduate Institute of M Sciences, Raebareli Road, Lucknow, Uttar Pradesh-206014, India ECR/16/Inst/UP/2013/RR-20	Dr. Sudeep Kumar
6.	Dr. Ram Manohar Lohia Institute of Medical Sciences Vibhuti Khand, Gomtinagar Lucknow, Uttar Pradesh,226010	Institutional Ethics Committee Dr. Ram Manohar Lohia Institute of Medical Sciences, Research Cell Office, Room No. 25, 2nd Floor, Administrative Block, RMLIMS Lucknow, Uttar Pradesh - 226010, India ECR/913/Inst/UP/2017/RR-20	Dr. Naveen Jamwal
7.	Sengupta Hospital & Research Institute Amravati Road, Ravi Nagar, Tilak Nagar, Gokulpeth Nagpur, Maharashtra, 440033	Sengupta Hospital & Research Institute Ethics Committee Ravinagar Square, Amaravati Road Nagpur, Maharashtra - 440033, India ECR/675/Inst/MH/2014/RR-20	Dr. Shantanu Pradeep Sengupta
8.	Manipal Hospital, Mysuru No. 85-86, Bangalore-Mysore Ring Road Junction Bannimantapa 'A' Layout, Siddiqui Nagar, Mandi Mohalla Mysuru, Karnataka, 570015	Institutional Ethics Committee Columbia Asia Hospital Mysore, No 85-86, Bangalore- Mysore Ring Road Junction, Bannimantapa A Layout, Mandi Mohalla, Mysuru, Karnataka -570015, India ECR/1106/Inst/KA/2018/RR-21	Dr. Keshavamurthy C B

9.	King George Hospital Maharanipeta, Visakhapatnam, Andhra Pradesh, 531011	Institutional Ethics Committee King George Hospital Maharanipeta, Collector Office Junction, Visakhapatnam, Andhra Pradesh - 531011, India ECR/197/Inst/KGH/2013/RR-20	Dr. Jenny Madhuri Gudivada
10.	Vijan Hospital & Research Centre, Dr. Vijan Hospital Marg, College Road Nashik, Maharashtra 422005	Vijan Hospital Ethics Committee, Vijan Cardiac and Critical Care Centre Dr. Vijan Hospital Marg, College Road, Nashik, Maharashtra - 422005, India ECR/406/Inst/MH/2013/RR-19	Dr. Vikrant Vinod Vijan
11.	G B Pant Institute of Post Graduate Medical Education and Research, 1, Jawaharlal Nehru Marg, 64 Khamba, Raj Ghat, New Delhi, Delhi-110002	Institutional Ethics Committee MAMC, Maulana Azad Medical College, 3rd Floor, Room 306A, Bhadur Shah Zafar Marg, New Delhi, Delhi-110002 ECR/329/Inst/DL/2013/RR-19	Dr. Mohit D Gupta
12.	Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, Delhi-110060	Sir Ganga Ram Hospital Ethics Committee, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, Delhi-110060 ECR/20/Inst/DL/2013/RR-19	Dr. Ashwani Mehta
13.	All India Institute of Medical Sciences (AIIMS), Bhubaneswar Sijua, Patrapada, Bhubaneswar, Odisha-751019	Institutional Ethics Committee AIIMS Bhubaneshwar, Sijua P/O Patrapada, Bhubaneshwar, Khordha, Orissa-751019, India ECR/534/Inst/OD/2014/RR-20	Dr. Rama Chandra Barik
14.	St. John's Medical College and Hospital, Sarjapur Road, Bengaluru, Karnataka-560034	Institutional Ethics Committee St. John's Medical College and Hospital, Sarjapur Road, Koramangala, Bengaluru Urban, Karnataka-560034, India ECR/238/Inst/KA/2013/RR-19	Dr. Kiron Varghese

15.	Jawaharlal Institute of Postgraduate Medical Education and Research, (JIPMER), JIPMER Campus Road, Gorimedu, Dhanvantari Nagar, Puducherry, Puducherry-605006	Institutional Ethics Committee Intervention Studies JIPMER, JIPMER Dhanvantari Nagar, Pondicherry-605006, India ECR/342/Inst/PY/2013/RR-19	Dr. Santhosh Satheesh
16.	KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi, Karnataka-590010	Institutional Ethics Committee, KLE University, KLE University's, KLE Dr. PK & MRC Nehru Nagar, Belagavi, Karnataka-590010, India ECR/211/Inst/KA/2013/RR-19	Dr. Veerappa Annasaheb Kothiwale
17.	Rhythm Heart Institute, Near Siddharth Bungalows, Sama-Savli Rd, Vadodara, Gujarat-390022	Rhythm Heart Institute Ethics Committee, Rhythm Heart Institute, Near Siddharth Bungalows, Sama-Savli Rd, Vadodara, Gujarat-390022 ECR/224/Inst/GJ/2013/RR-19	Dr. Nirav Chandiual Bhalani
18.	Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Medical Road, AMU Campus, Aligarh, Uttar Pradesh-202002	Institutional Ethics Committee Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Civil Line Koil, Aligarh, Uttar Pradesh-202002, India ECR/1418/Inst/UP/2020	Dr. Asif Hasan
19.	All India Institute of Medical Sciences (AIIMS),New Delhi, Ansari Nagar, New Delhi, Delhi-110029	Institutional Ethics Committee All India Institute of Medical Sciences, Old OT Block, Room No. 102, AIIMS Hospital, Ansari nagar, South Delhi, Delhi-110029, India ECR/538/Inst/DL/2014/RR-20	Dr. Ambuj Roy
20.	Sri Jayadeva Institute Cardiovascular Sciences Research, Jayanagar 9th Block, Bannerghatta Road, Bengaluru, Karnataka-560069	Sri Jayadeva Ethics Committee, Sri Jayadeva Institute Cardiovascular Sciences Research, Bannerghatta Road, 9th Block, Jayanagar Bengaluru, Urban, Karnataka-560069, India ECR/423/Inst/KA/2013/RR-19	Dr. Satvic C Manjunath

21.	Vardhaman Mahavir Medical College & Safdarjung Hospital, Mahatma Gandhi Road, Safdarjung Campus, Ansari Nagar West, New Delhi, Delhi-110029	Institutional Ethics Committee VMMC & SJH, VMMC and Safdarjung Hospital, Ring Road, Ansari Nagar West, New Delhi, Delhi-110029 ECR/593/Inst/DL/2014/RR-20	Dr. Preeti Gupta
22.	Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, 3/5, Patil Lane No. 1, Laxmi Nagar, Near K.B.H. Vidyalaya, Canada Corner, Nashik, Maharashtra-422005	Magna-care Ethics Committee, Chopda Medicare and Research Centre Pvt. Ltd., Magnum Heart Institute, Canada Corner, Nashik, Maharashtra-422005 ECR/79/Inst/MH/2013/RR-19	Dr. Manojkumar Bhavarilal Chopada
23.	S.P Medical College & Associate Group of Hospitals, Bikaner, Rajasthan-334003	Ethics Committee S.P Medical College Bikaner, S.P Medical College, Bikaner Pawanpuri, Bikaner, Rajasthan-334003, India ECR/27/SP/Inst/RJ/2013/RR-19	Dr. Devendra Kumar Agarwal
24.	WMF's Villoo Poonawalla Memorial Hospital, S. No. 156, Near Savali Corner, Soli Poonawalla Road (Solapur Road), Hadapsar Pune, Maharashtra-411028	Institutional Ethics Committee Villoo Poonawalla Memorial Hospital, Villoo Poonawalla Memorial Hospital, S. No. 156, Plot 1/3A, 3B, 1, 2/3, Solapur Road, Hadapsar Pune, Maharashtra-411028, India ECR/1642/Inst/MH/2022	Dr. Hemant Kokane
25.	Guru Nanak CARE Hospitals, 1-4-908/7/1, Near Raja Deluxe Theatre, Bakaram, Musheerabad, Hyderabad, Telangana-500020	CARE Hospitals, Institutional Ethics Committee, 6-3-248/2, CARE Hospital, In–patient Building, 4th Floor, Room No.-401, Road No. 1, Banjara Hills, Hyderabad, Telangana-500020, India ECR/94/Inst/AP/2013/RR-21	Dr. Johann Christopher
26.	Siddhartha Medical College & Government General Hospital, Ring Road, Gunadala, Vijaywada, Andhra Pradesh-520008	Institutional Ethics Committee SMC & GGH, Siddhartha Medical College & Government General Hospital, Ring Road, Gunadala, Vijayawada, Andhra Pradesh-520008	Dr. Srihari Barama

		ECR/633/Inst/AP/2014/RR-19	
27.	B M Birla Heart Research Centre, 1/1, National Library Avenue, Kolkata, West Bengal-700027	Institutional Ethics Committee B M Birla Heart Research Centre, Kolkata, 1/1, National Library Avenue, Kolkata, West Bengal-700027 ECR/55/Inst/WB/2013/RR-19	Dr. Dhiman Kahali

****